Press coverage about Petmed Express (NASDAQ:PETS) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Petmed Express earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.126825252115 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of PETS stock traded down $1.06 during trading hours on Friday, hitting $34.31. The company had a trading volume of 451,338 shares, compared to its average volume of 380,258. Petmed Express has a fifty-two week low of $31.81 and a fifty-two week high of $57.80. The firm has a market cap of $731.65 million, a P/E ratio of 18.85 and a beta of 0.54.

Petmed Express (NASDAQ:PETS) last released its earnings results on Monday, July 23rd. The company reported $0.62 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.63 by ($0.01). The business had revenue of $87.39 million for the quarter, compared to analyst estimates of $85.72 million. Petmed Express had a return on equity of 35.77% and a net margin of 14.42%. Petmed Express’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 earnings per share. analysts forecast that Petmed Express will post 2.28 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, August 10th. Shareholders of record on Friday, August 3rd were issued a dividend of $0.27 per share. The ex-dividend date was Thursday, August 2nd. This is a positive change from Petmed Express’s previous quarterly dividend of $0.25. This represents a $1.08 dividend on an annualized basis and a yield of 3.15%. Petmed Express’s dividend payout ratio is 59.34%.

PETS has been the topic of several recent analyst reports. BidaskClub lowered shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. ValuEngine lowered shares of Petmed Express from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 24th. Zacks Investment Research lowered shares of Petmed Express from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Craig Hallum restated a “sell” rating and issued a $32.00 price objective (down from $38.00) on shares of Petmed Express in a report on Monday, July 9th. Finally, CL King initiated coverage on shares of Petmed Express in a report on Friday, June 15th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $36.75.

In other Petmed Express news, Director Frank J. Formica sold 5,000 shares of the stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $41.78, for a total transaction of $208,900.00. Following the sale, the director now directly owns 48,500 shares in the company, valued at approximately $2,026,330. The transaction was disclosed in a document filed with the SEC, which is available through this link. 3.70% of the stock is owned by corporate insiders.

About Petmed Express

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Read More: What is Considered a Good Return on Equity (ROE)?

Insider Buying and Selling by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.